The biotech industry offers a compelling investment opportunity due to its potential for disruptive innovations and high ...

Its new use is based on an analysis of the phase 3 IMPACT study, which showed Trelegy was better than GSK’s already approved combinations Relvar/Breo Ellipta and Anoro Ellipta. Trelegy is also ...

The results aren’t all positive – Trelegy wasn’t able to improve on Relvar/Breo when it came to reducing asthma exacerbations and two other doses of Trelegy didn’t perform better than the ...

Please read this leaflet carefully before you start using TRELEGY ELLIPTA. This leaflet answers some common questions about TRELEGY ELLIPTA. It does not contain all the available information.

The company receives royalties from GSK plc (NYSE:GSK) for popular asthma and COPD products, including Relvar/Breo and Anoro, ...

Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Innoviva’s other innovative healthcare assets include infectious disease and ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Fluticasone furoate, umeclidinium, vilanterol 100/62.5/25mcg, 200/62.5/25mcg; per inh; dry pwd for oral inhalation. Trelegy Ellipta is supplied as a disposable light grey and beige plastic inhaler ...